Plain-English answer
DRG payment in China is a medical-insurance payment method that pays hospitals according to diagnosis-related groups rather than reimbursing every item separately. It is intended to control inpatient spending, standardize payment, and push hospitals to manage cost and quality inside a case-based payment envelope.
Policy context
NHSA's DRG/DIP payment reform three-year action plan built on 2019-2021 pilots and set a 2022-2024 schedule for broader implementation. The plan required eligible inpatient medical institutions in reform areas to be covered in staged annual progress, with areas starting later expected to complete coverage within two years. DRG reform therefore belongs to a national payment transformation, not a small demonstration project.
Operating model
Under DRG payment, hospitals face stronger pressure to manage length of stay, tests, drugs, consumables, and complications. A product that raises case cost can face resistance unless it prevents expensive complications, shortens stay, improves case-mix performance, or supports quality metrics. Departments may change behavior because the hospital can no longer rely as heavily on item-by-item billing to offset inefficient care.
Strategic reading
For market access, DRG payment means the economic buyer may be the hospital even when insurance technically pays. Companies need evidence showing how a product affects the case episode: procedure time, ICU use, readmissions, complications, and resource consumption. A U.S. DRG argument cannot simply be imported; Chinese grouping, local cost structures, and hospital incentives must be understood.
Decision test
For DRG Payment in China, the practical test is whether the analysis identifies the payer rule, hospital incentive, procurement route, affected product category, and implementation level. A page that only says China wants lower prices is not useful. The specific question is who changes behavior, under which rule, with what price, budget, quality, and access consequence.
Implementation detail
DRG Payment in China should be read through the full chain of Chinese healthcare finance: policy design, provincial or national implementation, hospital operating response, department-level behavior, and patient access. A reform can lower headline prices while still creating new questions about quality, supply, service availability, hospital incentives, and whether the savings reach patients in the form of usable care. The relevant evidence is therefore not only the announced policy, but also how hospitals, manufacturers, physicians, distributors, and insurers respond after implementation.
For market access, the page is most useful when it separates four layers. The first is the formal rule: who issued it, which products or services it covers, and when it applies. The second is the payment consequence: who loses margin, gains volume, absorbs cost, or changes budget risk. The third is the clinical consequence: whether physicians and hospitals can still choose the product, service, or workflow that fits the patient. The fourth is the commercialization consequence: whether a company should compete, differentiate, localize, redesign the channel, gather new evidence, or avoid the category. Without those layers, payment and procurement reform sounds abstract even though it directly determines adoption.